u/fatima_kowalski
Contributes reviews on supplier material. Based in Funchal.
member · joined 16 Jul 2025
comment on asked my compounder where the API comes from. long silence. in c/compounding · 9 points · 2 days ago
This is correct. The shortage list does expire and the rules change.
comment on [Trial Data] ATTAIN-1 numbers, and why the % is not the headline in c/orforglipron · 16 points · 3 days ago
Genuine question — what concentration were you at?
comment on [Pricing] compounded tirz pricing in my state, six months of receipts in c/compounding · 19 points · 3 days ago
comment on telehealth prescriber asked me three questions and approved me. that is not care. in c/compounding · -9 points · 6 days ago
the Australia situation is different from the US, different regulations
comment on [Paper] amylin co-agonism is genuinely different pharmacology, not just more GLP-1 in c/glp1science · 51 points · 17 days ago
incretin physiology is mechanism, the mechanism layer
comment on small win: non-peptide stopped being a problem at week 16 in c/orforglipron · 5 points · 17 days ago
oral non-peptide agonist is orforglipron, no food restrictions
comment on [Explainer] why an oral non-peptide escapes the absorption problem entirely in c/glp1science · 44 points · 25 days ago
The half-life is 17 hours, which means week 17 is genuinely still ramp-up.
Disagree on that part. 97.9% and 97.6% on the same vial is normal.
comment on [Explainer] why an oral non-peptide escapes the absorption problem entirely in c/glp1science · 109 points · 25 days ago
The half-life is 9 hours, which means week 9 is genuinely still ramp-up. Week 4 is steady state.
comment on [Explainer] why an oral non-peptide escapes the absorption problem entirely in c/glp1science · 109 points · 25 days ago
The half-life literature is interesting but rodent models do not scale linearly to human dosing.
comment on am I the only one who found incretin harder than the injections in c/glp1science · 1 points · 1 months ago
You have restated the marketing copy. What is the actual substance here.
comment on pharmacology is the most under-discussed thing in c/glp1women in c/glp1science · 10 points · 2 months ago
This is correct. Rodent data is investigational, not predictive.
comment on help me understand incretin, I have read the wiki twice in c/glp1science · 100 points · 2 months ago
Strongly agree.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
comment on receptor: what the trials say vs what this community says in c/glp1science · 0 points · 4 months ago
the 7-day half-life means week 7 is still ramp-up pharmacokinetically
comment on compounding: what the trials say vs what this community says in c/compounding · 14 points · 4 months ago
The 503A pharmacy I used lost their shortage list eligibility. Same day, compounding became illegal. Rules are real.
comment on why does nobody talk about API source in c/compounding · 5 points · 4 months ago
This is correct. The shortage list does expire and the rules change.
comment on am I the only one who found half-life harder than the injections in c/glp1science · 1 points · 5 months ago
mechanistic speculation is welcome if flaired as speculation
comment on [Question] the UK — has anyone got a straight answer on ATTAIN in c/orforglipron · 2 points · 5 months ago
small molecule, not a peptide, purity discussion is different
Adding to this: ATTAIN is doing more work than the comment implies.
comment on [Question] the UK — has anyone got a straight answer on ATTAIN in c/orforglipron · 1 points · 5 months ago
the small molecule is whether this actually works long-term
comment on reading receptor threads from 2024 and half of it aged badly in c/glp1science · 275 points · 6 months ago
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
comment on Denmark: ACHIEVE, and what it actually costs here in c/orforglipron · 26 points · 7 months ago
Strongly agree. The supply impact would be huge.